ArticleAnnals of medicine2025
First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolatuzumab vedotin (Pola) is an anti-CD79b monoclonal antibody-drug conjugate that has shown remarkable efficacy and safety in diffuse large B-cell lymphoma (DLBCL) patients. Based on the results of the phase III POLARIX trial, it has been approved for first-line treatment of DLBCL. However, real-world studies are limited, particularly those assessing the efficacy differences between Pola-based regimens and traditional chemotherapy.
methodsThis multicenter retrospective study analyzed clinical data from 64 newly diagnosed patients with advanced-stage, high-risk, or bulky DLBCL. Patients were categorized into the Pola plus chemotherapy (Pola) and traditional chemotherapy groups based on induction therapy.
resultsAfter excluding 6 patients who received fewer than four cycles of chemotherapy, 58 patients remained for efficacy analysis. The objective response rate after four cycles was 100% in the Pola group compared with 74.1% in the traditional chemotherapy group (
conclusionPola plus chemotherapy demonstrates superior efficacy and may prolong survival in patients with newly diagnosed advanced or high-risk DLBCL. However, it does not mitigate the unfavorable prognosis in patients with high P53 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.